Oct 01, 2025
Tianjin, China – Jecho Biopharmaceuticals Co., Ltd. (hereinafter referred to as “Jechobio”) has made another breakthrough in independently developed innovative drugs, offering a tribute to the National Day through scientific achievement.
Jechobio has received the “Drug Clinical Trial Approval Notice” from the National Medical Products Administration (NMPA), officially approving the clinical trial of JL19001 injection for the treatment of non-muscle-invasive bladder cancer (NMIBC).
Looking ahead, Jechobio will continue to uphold its innovation-driven mission, accelerate its drug development efforts, and contribute to advancing human health and well-being worldwide.
About JL19001 Injection
JL19001 injection is a Class I innovative drug jointly developed by Jecho laboratories, Inc. (USA) and Jecho Biopharmaceuticals Co., Ltd. It is a fusion protein composed of recombinant human serum albumin (HSA) and an IL-15Rα/IL-15 complex, designed to activate NK cells and CD8⁺ T cells, enhancing both innate and adaptive immune responses.
When used in combination with Bacillus Calmette–Guérin (BCG), JL19001 is intended to treat non-muscle-invasive bladder cancer (NMIBC) by helping avoid bladder removal surgery, thus improving patient survival rates and quality of life.
About Jechobio
Jecho Biopharmaceuticals Co., Ltd., (Jechobio) is a biotech company jointly established by renowned investment companies and Jecho Laboratories, Inc. (USA). Located in Tianjin Sino-Singapore Eco-City since January 2015, Jechobio specializes in research and development, chemistry, manufacturing and controls (CMC), and clinical development of biological therapeutics. Jechobio’s product pipelines are positioned to address unmet clinical needs, focusing on developing a new generation of globally innovative first-in-class (FIC) and best-in-class (BIC) biotherapeutics. Its product portfolio covers monoclonal antibodies, bispecific antibodies, recombinant proteins, oncolytic viruses, immunotoxins, and antibody-drug conjugates. With more than twenty programs in the pipeline, Jechobio has obtained nearly 10 clinical approvals, including those from China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA), with the lead product having completed Phase III clinical studies and ready for Biologics License Application (BLA).